MedTrace Logo

Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone

NCT00004645 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2005-06-24

No results posted yet for this study

Summary

OBJECTIVES:

I. Evaluate the effectiveness of plasma exchange in the treatment of acute severe attacks of inflammatory demyelinating disease in patients who have failed intravenous steroid therapy.

Conditions

  • Acute Disseminated Encephalomyelitis
  • Devic's Syndrome
  • Marburg's Variant of Multiple Sclerosis
  • Balo's Concentric Sclerosis
  • Acute Transverse Myelitis

Interventions

PROCEDURE

Plasma exchange

Sponsors & Collaborators

  • Mayo Clinic

    collaborator OTHER

  • National Institute of Neurological Disorders and Stroke (NINDS)

    lead NIH

Principal Investigators

  • Brian G. Weinshenker · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-01-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004645 on ClinicalTrials.gov